Results 221 to 230 of about 585,553 (296)

Treatment landscape from first‐ to third‐line therapy and quality of life data of patients with pancreatic cancer from the prospective German PARAGON (Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer) registry (IKF‐PARAGON study)

International Journal of Cancer, EarlyView.
What's New? Pancreatic cancer often is diagnosed at advanced stages. As a result, treatment regimens frequently are aggressive, with substantial side effects that impact quality of life (QoL). This study examined the treatment landscape, from neoadjuvant therapy to palliative care, in the context of QoL among pancreatic cancer patients in Germany. Most
Thorsten O. Goetze, Salah‐Eddin Al‐Batran, Ruediger Liersch, Lars Scheuer, Thomas Goehler, Ulrich Kaiser, Claudio Denzlinger, Stephan Brandl, Daniel Pink, Jens Uhlig, Michael Maasberg, Maria Loose, Marina Schaaf, Disorn Sookthai, Bianca Zäpf, Claudia Pauligk, Timursah Habibzade, Ralf‐Dieter Hofheinz, Christine Koch, for the AIO Study Group   +19 more
wiley   +1 more source

ProAE: an R package for graphical tools and standardized analysis of patient-reported outcomes and adverse events data. [PDF]

BMC Med Inform Decis Mak
Langlais B, Noble B, Fruth B, Truman M, Mazza GL, Ginos B, Mead-Harvey C, Lee M, Yee C, Rogak L, Meek E, Deal AM, Peipert JD, Thanarajasingam G, Basch E, Dueck AC.   +15 more
europepmc   +1 more source

Celso Emilio Ferreiro e Carlos Drummond de Andrade; un encontro inesperado [PDF]

, 2009
Gomes, Juliana
core  

Efficacy and safety of fruquintinib combined with albumin‐bound paclitaxel as second‐line therapy for advanced gastric cancer following failure of PD‐1 inhibitor‐containing treatment (TACTIC GC‐01): A phase II single‐arm study

International Journal of Cancer, EarlyView.
What's New? Anti‐angiogenic drugs have shown promising efficacy as a second‐line treatment for advanced gastric cancer. However, it remains unclear how alterations in the tumor microenvironment following first‐line immunotherapy may impact tumor angiogenesis and influence subsequent therapeutic outcomes. This single‐arm study prospectively explored the
Xiaoting Ma, Kai Ou, Xiu Liu, Biyang Cao, Wenwei Yang, Jingyu Lu, Letian Zhang, Qi Wang, Lizhen Gao, Zhichao Jiang, Yongkun Sun, Lin Yang   +11 more
wiley   +1 more source

A study on the efficacy of acupuncture combined with erector spinae plane blockade in patients undergoing thoracoscopic lung lobectomy. [PDF]

Medicine (Baltimore)
Huang J, Chen S, Wang L, Liu W, Zhan Y, Xiong M, Zhang J.   +6 more
europepmc   +1 more source

Efficacy, safety, and relapse outcomes of MAPK inhibitors in pediatric Langerhans cell histiocytosis: A real‐world study

International Journal of Cancer, EarlyView.
What's new? Mitogen‐activated protein kinase (MAPK) inhibitors are promising treatments for pediatric Langerhans cell histiocytosis (LCH), a rare heterogeneous neoplasm that often affects multiple organ systems. Which MAPK inhibitors are most effective against LCH remains uncertain.
Xue Tang, Jing‐jing Sun, Zhi Wan, Xiao‐yu Jing, Xia Guo, Ju Gao   +5 more
wiley   +1 more source

Three are better than two: redefining prophylaxis for postoperative nausea and vomiting. [PDF]

J Minim Invasive Surg
Kang H.
europepmc   +1 more source

No relevant pharmacokinetic interaction between the KRAS G12C inhibitor sotorasib and the direct oral anticoagulant rivaroxaban in healthy subjects

International Journal of Cancer, EarlyView.
What's New? Venous thromboembolism (VTE) is common in cancer patients, with direct oral anticoagulants, including rivaroxaban, recommended as first‐line therapy. However, oral anticoagulant use is limited due to the growing use of targeted therapy and concerns about drug‐drug interactions.
Esther M. Hollander, Alessandra I. G. Buma, Jenneke Leentjens, Paddy K. C. Janssen, Michel M. van den Heuvel, David M. Burger, Berber Piet, Rob ter Heine   +7 more
wiley   +1 more source

Pain Predicts Next-Day Fatigue in Adolescents and Young Adults Receiving Maintenance Treatment for Acute Lymphoblastic Leukemia. [PDF]

J Adolesc Young Adult Oncol
Klages KL, Pai ALH, Psihogios AM.
europepmc   +1 more source

Longitudinal changes in health‐related quality of life after a breast cancer diagnosis in sub‐Saharan Africa: Evidence from the prospective ABC‐DO cohort

International Journal of Cancer, EarlyView.
What's New? Breast cancer is now the most common malignancy among women in sub‐Saharan Africa (SSA). Its impact on survivors’ quality of life and Global Health Status (GHS), however, remains inadequately studied in this setting. Here, using data from the African Breast Cancer‐Disparities in Outcomes (ABC‐DO) study, the authors examined GHS over time in
Shamsudeen Mohammed, Moses Galukande, Allen Naamala, Groesbeck Parham, Leeya Pinder, Angelica Anele, Shadrach Awa Offiah, Annelle Zietsman, Joachim Schüz, Valerie McCormack, Isabel dos‐Santos‐Silva   +10 more
wiley   +1 more source